News and Announcements
AEIT finalises Joint Venture negotiations
- Published November 14, 2013 5:19PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
AEIT this week has finalised negotiations with a Brisbane based Bus Operator to establish a Joint Venture Subsidiary Company where AEIT will hold 75% equity share.
The JV Company will become the Public Transport Operating Arm where it will be able to:
- Tender to provide (Zero Emission) Public Transport Bus/Tram Services
- Provide end to end (Supply, Install, Operate) Public Transport solution for clients (e.g. Airports) looking to implement ZERO Emission transport.
- Manage Maintenance Contract for OLEV Vehicles
JV Partner is an experience public transport operator and their contribution in the new company would assist AEIT to further its commercialisation strategy by having the ability to provide end to end solution to local councils and State Governments to reduce their Green House Gas Emissions and meet their emission targets by 2020.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
